1. "Sujata Patil"
  2. "Sarat Chandarlapaty"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (10)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (28)
  2. Biostatistics Service (28)
  3. Breast Medicine Service (28)
  4. Department of Medicine (28)
  5. Epidemiology and Biostatistics (28)
  6. GSK Faculty (28)

More Groups

People
  1. Sarat Chandarlapaty (28)
  2. Sujata Patil (28)
  3. Clifford Hudis (25)
  4. Shanu Modi (23)
  5. Larry Norton (14)
  6. Gabriella D'Andrea-Carlino (13)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (1)
  6. 2017 (1)

More Years

Publications
  1. Cancer Research (10)
  2. Journal of Clinical Oncology (8)
  3. Clinical Cancer Research (3)
  4. Clinical Breast Cancer (2)
  5. Breast Cancer Research (1)
  6. Breast Cancer Research and Treatment (1)

More Publications

Publishers
  1. American Association for Cancer Research (13)
  2. American Society of Clinical Oncology (8)
  3. Elsevier Inc. (2)
  4. Biomed Central Ltd (1)
  5. Nature Publishing Group (1)
  6. Nature Research (1)

More Publishers

Results (28)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Journal Article

    Ferraro, E.; Singh, J.; Patil, S.; Razavi, P.; Modi, S.; Chandarlapaty, S.; Barrio, A. V.; Malani, R.; Mellinghoff, I. K.; Boire, A.; more...
    npj Breast Cancer (2022)

    Fulltext@MSK | Save
  • A phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Drago, J. Z.; Shah, P. D.; Wang, R.; Pareja, F.; Ratzon, F.; Iasonos, A.; Patil, S.; Rosen, N.; Fornier, M. N.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with human epidermal growth receptor 2 overexpressing metastatic breast cancer: 5-year follow-up
    Journal Article

    Wang, R.; Smyth, L. M.; Iyengar, N.; Chandarlapaty, S.; Modi, S.; Jochelson, M.; Patil, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Wang, R.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; more...
    Breast Cancer Research (2017)

    Fulltext@MSK | Save
  • Biomarkers that predict sensitivity to heat shock protein 90 inhibitors
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Iyengar, N.; Morris, P. G.; Corben, A. D.; Patil, S.; Akram, M.; Towers, R.; Sakr, R. A.; King, T. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: Overall survival and updated progression-free survival results from a phase II study
    Journal Article

    Smyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; more...
    Breast Cancer Research and Treatment (2016)

    Fulltext@MSK | Save
  • Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling
    Meeting Abstract

    Gucalp, A.; Proverbs-Singh, T. A.; Razavi, P.; Chandarlapaty, S.; Patil, S.; Ross, D. S.; Zehir, A.; Baselga, J.; Hudis, C. A.; Traina, T. A.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling
    Meeting Abstract

    Morikawa, A.; De Stanchina, E.; Patil, S.; Chandarlapaty, S.; Li, B. T.; Norton, L.; Seidman, A. D.
    Cancer Research (2016)

    Fulltext@MSK | Save